Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Hampshire for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Hampshire only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Hampshire (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Gina Divenuti (NPI 1912958703)

Field	Value
Entity Type	Individual
Organization	Gina Divenuti
Address	250 Pleasant St
City	Concord
State	NH
ZIP	03301
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 15, 2006

Payer Source	Total Paid
Medicare	$1M
Medicaid	$0

Key Findings

The provider’s Medicare billing profile is dominated by oncology infusion and related outpatient management services, with J9271 (Injection, pembrolizumab) representing the single largest line item at 19.8K claims and $772.2K revenue (75.8% of this provider's total Medicare revenue). Additional chemotherapy administration and infusion codes (96413, 96417, 96411, G0498) also appear on the top-25 list, indicating an operational focus on in-office systemic therapy delivery alongside office visits. This code mix is consistent with the listed taxonomy of Hematology & Oncology Physician and suggests an infusion-centered oncology practice model.

Revenue is highly concentrated: the precomputed top-3 Medicare codes (J9271, 99214, 99213) account for 88.1% of this provider’s total Medicare revenue. J9271 alone contributes 75.8% of Medicare revenue, while 99214 and 99213 together add the bulk of the remaining share, which highlights sensitivity of overall revenue to utilization or payer changes affecting these specific codes. Such concentration means shifts in access to or reimbursement for pembrolizumab or changes in outpatient visit patterns could materially affect reported Medicare revenue.

This provider is effectively single-payer in the available dataset: Total Medicare revenue is $1M while there is no Medicaid billing on file (none). The absence of Medicaid activity in the records makes Medicare the primary — and for reporting purposes the sole — source of public-payer revenue, which has implications for payer-mix exposure and contracting analyses focused on Medicare fee schedules and utilization patterns. Analysts should treat Medicaid-related market access or state-level program participation as unknown from these claims alone.

Competitive standing is mixed across specific codes: for the revenue-driving oncology drug J9271 the provider ranks #406 of 1841 nationally (77th percentile) which the source labels as typical, unremarkable volume relative to peers, even though it generates the majority of the provider’s Medicare dollars. In contrast, office visit codes 99214 (851 claims, $79.1K revenue) and 99213 (753 claims, $45.9K revenue) rank in the 96th and 97th percentiles nationally and are described as notably above typical national volume, indicating the provider sees substantially more outpatient visit volume than most peers. This pattern suggests a practice that pairs a standard national-level pembrolizumab infusion workload with a higher-than-typical ambulatory visit throughput.

The practice shows a substantial ambulatory workload in addition to drug administration: 99214 accounts for 851 claims ($79.1K) and 99213 for 753 claims ($45.9K), together representing the two largest non-drug revenue contributors. The notably above-typical national volume labels for these E/M codes imply frequent patient follow-up and management visits, consistent with ongoing systemic-therapy monitoring and chronic oncology care. For payer negotiations or network capacity planning, these elevated E/M volumes are as important as drug reimbursement because they drive visit-based revenue and staffing needs.

Chemotherapy administration codes reflect an operational capacity for infusion services beyond pembrolizumab: 96413 shows 413 claims and $42.5K revenue (4.2% of Medicare revenue) and ranks #1069 of 7514 (86th percentile, labeled typical), while add-on and infusion-continuation codes such as 96417, 96411, and 96415 also appear in the top-25 with nontrivial claim counts. G0498 (56 claims, $12K) further indicates use of office/clinic-initiated infusion processes that continue in the community setting. Together these administration codes corroborate an infusion suite infrastructure with routine chemotherapy and supportive medication delivery.

The provider’s longevity in Medicare is notable: the NPI was enumerated on 2006-05-15 (~20 years ago), indicating a long tenure in the program. This extended enrollment suggests established referral relationships and sustained Medicare billing history that can be relevant when assessing network stability, patient continuity, or historical utilization trends. Analysts should consider this tenure when benchmarking performance or when evaluating the likelihood of stable future revenue streams.

Operational and access implications follow from the payer mix and code concentration: with $1M in Medicare revenue and no Medicaid billing on file, the provider’s exposure is concentrated both by payer and by a few high-revenue codes (top 3 = 88.1%). This profile could increase financial sensitivity to formulary, reimbursement, or utilization-management changes that affect high-revenue drugs like J9271. For state Medicaid planning or efforts to expand access, the lack of Medicaid billing flagged here should trigger outreach or verification if inclusion of this provider in Medicaid networks is a strategic objective.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

34 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	19,800	$40	$772.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	850	$90	$79.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	750	$60	$45.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	410	$100	$42.5K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	60	$220	$12K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	70	$160	$10.8K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	60	$130	$7.6K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	130	$50	$6.5K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	260	$20	$6K
J0185	Injection, aprepitant, 1 mg	5,980	$1	$6K

Showing 1–10 of 34

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 34 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Hampshire Distribution

Gina Divenuti — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Hampshire

Full comparison — all codes billed, vs. state median

34 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	10	10,000	$40	$440.2K
96413	2	20	140	$100	$15.8K
99214	46	3,150	110	$80	$13.2K
99233	554	600	70	$90	$10.9K
G0498	2	10	50	$220	$10.6K
99232	621	990	70	$60	$9.8K
99213	37	2,900	70	$50	$6.9K
99215	345	1,080	40	$110	$6.8K
99205	53	440	20	$140	$4.9K
J0185	1	10	2,600	$1	$4.7K

Showing 1–10 of 34

Related Providers

Other providers that share a Tax Identification Number (TIN) with Gina Divenuti, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Elliot Professional Services	NH	Internal Medicine Physician	$0	$12.8M
Exeter Hospital Inc	NH	General Acute Care Hospital	$0	$12.5M
Maxwell Elia	NH	Ophthalmology Physician	$2.3M	$0
Ahad Fazelat	NH	Ophthalmology Physician	$2.1M	$0
Anthony Correnti	NH	Ophthalmology Physician	$1.5M	$0
Frederick Briccetti	NH	Hematology & Oncology Physician	$861.3K	$0
Josy Mathew	NH	Hematology & Oncology Physician	$452.4K	$0
Anthony Squillaro	NJ	Thoracic Surgery (Cardiothoracic Vascular Surgery) Physician	$415.6K	$0
Peter Crow	NH	Hematology & Oncology Physician	$415.1K	$0
Michael Buff	NH	Hematology & Oncology Physician	$387.2K	$0

Nearby Providers

Other providers in the same ZIP code as Gina Divenuti, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Community Bridges	NH	Case Management Agency	$0	$265.5M
Riverbend Community Mental Health, Inc.	NH	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$118.4M
Granite State Independent Living	NH	In Home Supportive Care Agency	$0	$74.7M
Ascentria Community Services, Inc	NH	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$52.6M
Ascentria Community Care, Inc	NH	Voluntary or Charitable Agency	$0	$50.3M
Concord Hospital, Inc.	NH	General Acute Care Hospital	$0	$28.8M
Concord Pediatric Dentistry	NH	Pediatric Dentistry	$0	$13.6M
New England Life Care, Inc.	NH	Home Infusion Therapy Pharmacy	$0	$11.4M
New Hampshire Home Care Providers LLC	NH	In Home Supportive Care Agency	$0	$11M
Brain Injury Association Of Nh	NH	Case Management Agency	$0	$11M

Gina Divenuti — Billing Profile & Reimbursement Data

Sign up for Gina Divenuti — Billing Profile & Reimbursement Data policy alerts

Gina Divenuti — Billing Profile & Reimbursement Data

Sign up for Gina Divenuti — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References